Cargando…

Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease

Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedroso, Ivonne, Garcia, Marité, Casabona, Enrique, Morales, Lilia, Bringas, Maria Luisa, Pérez, Leslie, Rodríguez, Teresita, Sosa, Ileana, Ricardo, Yordanka, Padrón, Arnoldo, Amaro, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981245/
https://www.ncbi.nlm.nih.gov/pubmed/29862060
http://dx.doi.org/10.3390/bs8050051
_version_ 1783328006652035072
author Pedroso, Ivonne
Garcia, Marité
Casabona, Enrique
Morales, Lilia
Bringas, Maria Luisa
Pérez, Leslie
Rodríguez, Teresita
Sosa, Ileana
Ricardo, Yordanka
Padrón, Arnoldo
Amaro, Daniel
author_facet Pedroso, Ivonne
Garcia, Marité
Casabona, Enrique
Morales, Lilia
Bringas, Maria Luisa
Pérez, Leslie
Rodríguez, Teresita
Sosa, Ileana
Ricardo, Yordanka
Padrón, Arnoldo
Amaro, Daniel
author_sort Pedroso, Ivonne
collection PubMed
description Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson’s disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition.
format Online
Article
Text
id pubmed-5981245
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-59812452018-06-01 Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease Pedroso, Ivonne Garcia, Marité Casabona, Enrique Morales, Lilia Bringas, Maria Luisa Pérez, Leslie Rodríguez, Teresita Sosa, Ileana Ricardo, Yordanka Padrón, Arnoldo Amaro, Daniel Behav Sci (Basel) Article Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson’s disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition. MDPI 2018-05-21 /pmc/articles/PMC5981245/ /pubmed/29862060 http://dx.doi.org/10.3390/bs8050051 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pedroso, Ivonne
Garcia, Marité
Casabona, Enrique
Morales, Lilia
Bringas, Maria Luisa
Pérez, Leslie
Rodríguez, Teresita
Sosa, Ileana
Ricardo, Yordanka
Padrón, Arnoldo
Amaro, Daniel
Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
title Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
title_full Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
title_fullStr Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
title_full_unstemmed Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
title_short Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
title_sort protective activity of erythropoyetine in the cognition of patients with parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981245/
https://www.ncbi.nlm.nih.gov/pubmed/29862060
http://dx.doi.org/10.3390/bs8050051
work_keys_str_mv AT pedrosoivonne protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT garciamarite protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT casabonaenrique protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT moraleslilia protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT bringasmarialuisa protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT perezleslie protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT rodriguezteresita protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT sosaileana protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT ricardoyordanka protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT padronarnoldo protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease
AT amarodaniel protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease